Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on Sales

Lexaria Bioscience (LEXX) FCF Margin (2017 - 2026)

Lexaria Bioscience's FCF Margin history spans 10 years, with the latest figure at 11023.44% for Q1 2026.

  • Quarterly results put FCF Margin at 11023.44% for Q1 2026, down 1016258.0% from a year ago — trailing twelve months through Feb 2026 was 2558.49% (down 114206.0% YoY), and the annual figure for FY2025 was 1483.88%, down 40650.0%.
  • FCF Margin for Q1 2026 was 11023.44% at Lexaria Bioscience, down from 1518.68% in the prior quarter.
  • In the past five years, FCF Margin ranged from a high of 427.32% in Q1 2024 to a low of 63911.95% in Q3 2022.
  • The 5-year median for FCF Margin is 1789.21% (2025), against an average of 6649.66%.
  • The sharpest move saw FCF Margin plummeted -6389432bps in 2022, then surged 5863665bps in 2023.
  • Year by year, FCF Margin stood at 1295.15% in 2022, then skyrocketed by 40bps to 781.11% in 2023, then crashed by -91bps to 1495.57% in 2024, then dropped by -2bps to 1518.68% in 2025, then plummeted by -626bps to 11023.44% in 2026.
  • According to Business Quant data, FCF Margin over the past three periods came in at 11023.44%, 1518.68%, and 2059.74% for Q1 2026, Q3 2025, and Q2 2025 respectively.